Gliflozins in Cardiac and Renal Disease Gliflozins—sodium–glucose cotransporter 2
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of
symptoms and functional limitations, and have a poor quality of life. By targeting …

Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2
diabetes mellitus (T2DM), particularly in low-and middle-income countries. To effectively …

Objectives This report describes the baseline clinical profiles and management of DELIVER
(Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction …

Background: Frailty is increasing in prevalence. Because patients with frailty are often
perceived to have a less favorable risk/benefit profile, they may be less likely to receive new …

Background Guidelines recommend early initiation of multiple guideline-directed medical
therapies (GDMTs) to reduce mortality/rehospitalization in patients with heart failure and …

Chronic kidney disease (CKD) and heart failure affect many people worldwide. Despite the
availability of pharmacological treatments, both diseases remain associated with …